











































Risk factors for poor outcomes in hospitalised COVID-19 patients
Citation for published version:
Li, Y, Chung, A, Dighero, I, Dozier, M, Horne, M, McSwiggan, E, Shamsuddin, A & Nair, H 2021, 'Risk
factors for poor outcomes in hospitalised COVID-19 patients: a systematic review and meta-analysis',
Journal of Global Health, vol. 11, pp. 10001. https://doi.org/10.7189/jogh.11.10001
Digital Object Identifier (DOI):
10.7189/jogh.11.10001
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Global Health
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.





























































www.jogh.org • doi: 10.7189/jogh.11.10001 1 2021  •  Vol. 11 •  10001
You Li1, Thulani Ashcroft1*, 
Alexandria Chung1*,  
Izzie Dighero1*, Marshall Dozier2*, 
Margaret Horne1,3*,  
Emilie McSwiggan1*,  
Azwa Shamsuddin1*, Harish Nair1;  
for the Usher Network for 
COVID-19 Evidence Reviews 
(UNCOVER) group
1 Usher Institute, University of Edinburgh, 
Edinburgh, UK
2 Information Services, University of Edinburgh, 
Edinburgh, UK
3 Centre for Clinical Brain Sciences, University 
of Edinburgh, Edinburgh, UK
* Listed alphabetically.
Correspondence to:
Prof. Harish Nair 
Usher Institute 
University of Edinburgh 
Scotland, UK EH8 9JS 
Harish.Nair@ed.ac.uk
Risk factors for poor outcomes in 
hospitalised COVID-19 patients: A 
systematic review and meta-analysis
Electronic supplementary material: 
The online version of this article contains supplementary material.
© 2021 The Author(s)
JoGH © 2021 ISGH
Background Understanding the risk factors for poor outcomes among 
COVID-19 patients could help identify vulnerable populations who 
would need prioritisation in prevention and treatment for COVID-19. 
We aimed to critically appraise and synthesise published evidence on 
the risk factors for poor outcomes in hospitalised COVID-19 patients.
Methods We searched PubMed, medRxiv and the WHO COVID-19 lit-
erature database for studies that reported characteristics of COVID-19 
patients who required hospitalisation. We included studies published 
between January and May 2020 that reported adjusted effect size of any 
demographic and/or clinical factors for any of the three poor outcomes: 
mortality, intensive care unit (ICU) admission, and invasive mechanical 
ventilation. We appraised the quality of the included studies using Jo-
anna Briggs Institute appraisal tools and quantitatively synthesised the 
evidence through a series of random-effect meta-analyses. To aid data 
interpretation, we further developed an interpretation framework that 
indicated strength of the evidence, informed by both quantity and qual-
ity of the evidence.
Results We included a total of 40 studies in our review. Most of the in-
cluded studies (29/40, 73%) were assessed as “good quality”, with as-
sessment scores of 80 or more. We found that male sex (pooled odds 
ratio (OR) = 1.32 (95% confidence interval (CI) = 1.18-1.48; 20 studies), 
older age (OR = 1.05, 95% CI = 1.04-1.07, per one year of age increase; 
10 studies), obesity (OR = 1.59, 95% CI = 1.02-2.48; 4 studies), diabetes 
(OR = 1.25, 95% CI = 1.11-1.40; 11 studies) and chronic kidney diseases 
(6 studies; OR = 1.57, 95% CI = 1.27-1.93) were associated with increased 
risks for mortality with the greatest strength of evidence based on our in-
terpretation framework. We did not find increased risk of mortality for 
several factors including chronic obstructive pulmonary diseases (5 stud-
ies), cancer (4 studies), or current smoker (5 studies); however, this does 
not indicate absence of risk due to limited data on each of these factors.
Conclusion Male sex, older age, obesity, diabetes and chronic kidney 
diseases are important risk factors of COVID-19 poor outcomes. Our 
review provides not only an appraisal and synthesis of evidence on the 
risk factors of COVID-19 poor outcomes, but also a data interpretation 
framework that could be adopted by relevant future research.
Cite as: Li Y, Ashcroft T, Chung A, Dighero I, Dozier M, Horne M, Emiie McSwiggan E, Shamsuddin A, Nair 
H; for the Usher Network for COVID-19 Evidence Reviews (UNCOVER) group. Risk factors for poor outcomes 
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As of 9 December 2020, the global total number of deaths due to COVID-19 hit 1.5 million. It is imperative to 
understand the risk factors for COVID-19 mortality as well as other poor outcomes such as intensive care unit 
(ICU) admission and invasive mechanical ventilation (IMV). This could help identify vulnerable populations 
who might need prioritisation in terms of protection (eg, “shielding”), prevention (eg, through vaccination), 
and priority access to hospital-based care. This could also help with the promotion of short-and-longer-term 
behavioural changes (eg, smoking).
An earlier study [1] identified older age as an important risk factor for COVID-19 mortality, based on 191 
patients in Wuhan, China. Some more recent large scale studies [2-4] further identified more risk factors for 
COVID-19 mortality, such as being male, obesity, diabetes, and cancer. However, these large-scale studies 
were mainly from the UK and the USA, and there is a need for synthesised evidence incorporating data from 
all available sources across the globe. To this end, we conducted a systematic review and meta-analysis to syn-
thesise all available evidence regarding the risk factors for poor outcomes in hospitalised COVID-19 patients.
METHODS
This systematic review is registered with PROSPERO (CRD42020190031) and is reported according to the 
PRISMA checklist (Appendix S1 in the Online Supplementary Document).
Literature search
The search strategy was designed to identify studies reporting characteristics of patients with COVID-19 who 
required hospitalisation. We searched PubMed, medRxiv and the WHO COVID-19 literature database (Ap-
pendix S2 in the Online Supplementary Document) for papers published between January and May 2020. 
The PubMed search was based on the sensitive COVID-19 string developed by Shokraneh and colleagues [2], 
combined with a string of MeSH and freetext terms relating to clinical features, study design or outcomes. The 
search was then adapted for the other databases. The searches were carried out by one reviewer (MD). Only 
papers in English were considered for inclusion.
Literature selection
After excluding duplicates, each study was screened by two independent reviewers from a group of six review-
ers (TA, AC, ID, MH, EM and AS) using the following selection criteria (Box 1). Any disagreements on the se-
lection were resolved through joint discussions among the six reviewers.
Data extraction
A tailored Excel spreadsheet was used to record data extraction. The following information was collected for 
each included study: author, publication year, study period and location, study design, outcome(s) of interest, 
number of patients included, risk group(s) reported and the corresponding reference group, adjusted effect size 
Box 1. Selection criteria
Inclusion criteria
• Reported data for hospitalised COVID-19 infected patients; AND
• Reported data for demographic and/or clinical factors associated with the following poor outcome measures: 
mortality, ICU admission, and IMV; AND
• Case identification was confirmed by: PCR, nucleic acid test, molecular testing, “laboratory diagnosed/con-
firmed”; AND
• Reported adjusted OR/RR/HR, with age and sex being considered for adjustment as a minimum; AND
• Used clearly defined demographic and/or clinical factors.
Exclusion criteria
• Only included patients who had been hospitalised prior to the outcome(s) of interest; OR
• Definitions were not clear for risk and/or reference group(s); OR
• Reviews, editorials and randomised clinical trials where data in the control arm (placebo group) could not be 
extracted; OR
• Case series with no comparison group; OR
• Data were reported by another study (in which case the study with the most comprehensive data was included)
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with confidence interval, etc. Data extraction was conducted by a single reviewer and was checked by a sec-
ond reviewer from a group of six reviewers (TA, AC, ID, MH, EM and AS). Any disagreements were resolved 
through joint discussions among the six reviewers, with oversight from YL and HN.
Quality assessment
For each included study, quality assessment was conducted using the Joanna Briggs Institute Critical Appraisal 
tool (https://joannabriggs.org/critical-appraisal-tools). Depending on the study design, a questionnaire of ten 
or eleven questions was completed independently by two reviewers from a group of six reviewers (TA, AC, ID, 
MH, EM and AS), with any disagreements discussed jointly among the group. Each of the quality assessment 
questions has four possible answers: yes (indicating good quality), no (indicating bad quality), unknown and 
not applicable. In order to generate comparable quality scores across different studies, we calculated the per-
centage of “yes” among all questions (excluding “not applicable”) as the overall score of quality, which could 
range between 0 and 100. We defined good quality as having a quality assessment score of 80 or more.
Meta-analysis
Main analysis
For each risk factor per outcome (ie, mortality, ICU admission and IMV), we conducted a meta-analysis of 
odds ratio (OR) only if three or more studies were available. As heterogeneity was expected among studies in 
terms of study population and methodology, we decided, a priori, to use a random-effects model (using re-
stricted maximum likelihood estimator) for the meta-analysis. Visual inspection of the funnel plot and Egger’s 
test were used for assessing publication bias.
Sensitivity analysis
We considered two sets of sensitivity analyses. Sensitivity analysis 1 excluded studies that had the highest ef-
fect size if the pooled effect size in the main analysis was statistically significant (ie, 95% confidence interval 
did not include 1); this is to exclude the effect of a single outlier that might drive the pooled estimate to the 
level of statistical significance. Sensitivity analysis 2 excluded studies that had quality scores of less than 80. 
Similar to the main analysis, sensitivity analyses were conducted only if three or more studies were available.
Data interpretation criteria
For each risk factor per outcome, a decision framework for data interpretation was designed to assess the 
strength of the association between these risk factors and outcomes (Figure 1). In brief, if a meta-analysis was 
conducted, the interpretation could be “increased risk”, “possibly increased risk”, “possibly no increased risk” 
or “no increased risk”, depending on the consistency in the statistical significance of results between the main 
analysis and sensitivity analyses; the interpretation would be “increased risk” or “no increased risk” only if find-
ings between the main and sensitivity analyses were consistent. When a meta-analysis was not conducted, the 
interpretation would be either “possibly increased risk” or “unknown”.
Figure 1. Decision flowchart presenting data interpretation criteria. *Defined as the effect size being between 0.99 and 
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Statistical software
All statistical analyses and visualisation were conducted using R (version 3.6.1) (Foundation for Statistical 
Computing, Vienna, Austria).
RESULTS
After excluding duplicates, 2643 records were screened by title and abstract, leaving 832 records that were 
further screened by full-text. As a result, a total of 40 studies were included [5-44] in this review (Figure 2). 
We also summarised the prior systematic reviews identified through our literature search (Table S1 in the On-
line Supplementary Document).
Most of the included studies (38/40, 95%) were from China, USA and European countries. As a poor out-
come, mortality was reported in 31 studies; ICU admission in eight studies; and IMV in seven studies. Most 
of the included studies (29/40, 73%) were assessed as “good quality”, with an assessment score of 80 or more 
(Table S2 in the Online Supplementary Document). All studies were included in the meta-analysis with the 
exception for the study of Mahta et al [27] that focused on angiotensin-converting enzyme inhibitors (ACEi) 
and angiotensin II receptor blockers (ARB); we did not have enough studies that reported these two factors for 
meta-analysis. (Table 1) No publication bias was indicated in any meta-analyses.
Risk factors for mortality
Risk factors that were associated with increased risk for mortality
Being male was shown to be associated with higher risk for mortality; the pooled OR was 1.32 (95% confidence 
interval (CI) = 1.18-1.48) in the main analysis based on 20 studies (Figure 3), and was 1.31 (95% CI = 1.17-
1.47) and 1.32 (95% CI = 1.18-1.47) in two 
sensitivity analyses.
Two types of studies were available that re-
ported age as a risk factor for mortality: the 
first type used age as a continuous variable 
(with no specific reference age group) where 
the interpretation was the average risk per 
Figure 2. PRISMA flow diagram presenting literature selection process.
Figure 3. Forest plots showing meta-analysis results for mortality. 
Panel A. Sex. Panel B. Age. N – number of subjects, QA – quality 
assessment score.
Figure 2
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one year of increase in age among the age range of the study participants; the second type used age groups 
and selected one age group as the reference. For the first type of study, results from our meta-analysis showed 
that the pooled OR was 1.05 (95% CI = 1.04-1.07) per one year of age increase in the main analysis based on 
10 studies (Figure 3), and was 1.05 (95% CI = 1.04-1.06) for both sensitivity analyses. For the second type of 
study, due to varied reporting of age groups, we were unable to conduct a meta-analysis for any specific age 
groups but results were broadly consistent with those from the first type of studies (Table S3 in the Online 
Supplementary Document).
Similar to varied age groupings, BMI was grouped differently among studies and we were only able to conduct 
a meta-analysis for obesity (BMI>30) compared to non-obesity (BMI<30), based on four studies. Obesity was 
shown to increase mortality risk with the pooled OR of 1.59 (95% CI = 1.02-2.48) in the main analysis (Fig-
ure 4) and 1.28 (95% CI = 1.00-1.64) in the sensitivity analysis that excluded the study with the largest effect 
size. Studies that were not included in the main analysis were summarised in Table S4 in the Online Supple-
mentary Document.
Table 1. Characteristics of studies included in the review
Study Location, Country Study period Mortality ICU IMV Included in  meta-analysis
Alberici, 2020 [6] Brescia, Italy Mar 2020 Y N N Y
Al-sabah, 2020 [5] Kuwait Feb-May 2020 N Y N Y
Bianchetti, 2020 [7] Brescia, Italy Feb-Apr 2020 Y N N Y
Chen, 2020a [9] Shanghai, China Jan-Feb 2020 N Y N Y
Chen, 2020b [10] China Jan 2020 Y N N Y
Chen, 2020c [8] Wuhan, China Jan-Mar 2020 Y N N Y
Chen, 2020d [11] Wuhan, China Jan-Mar 2020 Y N N Y
Chroboczek, 2020 [12] Leman, France Mar-Apr 2020 N N Y Y
Cummings, 2020 [13] New York, USA Mar-Apr 2020 Y N N Y
Docherty, 2020 [14] UK Feb-Apr 2020 Y N N Y
Foy, 2020 [15] USA Mar-Apr 2020 Y N N Y
Gaibazzi, 2020 [16] Parma, Italy Mar 2020 Y N N Y
Gao, 2020 [17] China Not reported Y N N Y
Giacomelli, 2020 [18] Italy Feb-Mar 2020 Y N N Y
Giorgi-Rossi, 2020 [19] Lombardy, Italy Feb-Apr 2020 Y N N Y
Huang, 2020 [20] Hubei, China Jan-Mar 2020 Y N N Y
Hur, 2020 [21] Chicago, USA Mar-Apr 2020 N N Y Y
Kalligeros, 2020 [22] USA Feb-Apr 2020 N Y Y Y
Kim, 2020 [23] USA Mar-May 2020 Y Y N Y
Klang, 2020 [24] New York, USA Mar-May 2020 Y N N Y
Li, 2020 [25] Wuhan, China Jan-Mar 2020 Y N N Y
Liu, 2020 [26] China Feb 2020 Y N N Y
Mehta, 2020 [27] USA Mar-Apr 2020 N Y Y N
Murillo-Zamora, 2020 [28] Mexico Not reported Y N N Y
Palaiodimos, 2020 [29] New York, USA Mar 2020 Y N Y Y
Petrilli, 2020 [30] USA Mar-Apr 2020 Y N N Y
Regina, 2020 [31] Switzerland Mar 2020 N N Y Y
Reyes, 2020 [32] New York, USA Mar 2020 Y N N Y
Sapey, 2020 [33] Birmingham, UK Mar 2020 Y N N Y
Shi, 2020a [36] Wuhan, China Jan-Feb 2020 Y N N Y
Shi, 2020b [34] Wuhan, China Not reported Y Y N Y
Shi, 2020c [35] Wuhan, China Not reported Y Y N Y
Simonnet, 2020 [37] Lille, France Feb-Apr 2020 N N Y Y
Tang, 2020 [38] Wuhan, China Jan-Feb 2020 Y N N Y
Wang, 2020a [39] Wuhan, China Jan-Feb 2020 Y N N Y
Wang, 2020b [40] Changsha, China Not reported N Y N Y
Wang, 2020c [41] Wuhan, China Not reported Y N N Y
Xie, 2020 [42] Wuhan, China Jan-Feb 2020 Y N N Y
Zhang, 2020a [44] Wuhan, China Jan-Feb 2020 Y N N Y
Zhang, 2020b [43] Wuhan, China; London, UK Not reported Y N N Y
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Based on the meta-analysis among 11 studies, diabetes (of any type) was shown to increase mortality risk with 
an OR of 1.25 (95% CI = 1.11-1.40; Figure 4). The two sensitivity analyses showed similar results to the main 
analysis (OR = 1.23, 95% CI: 1.10-1.38 and OR = 1.23, 95% CI = 1.09-1.39). In addition to the 11 studies that 
reported diabetes of any type and were included in the meta-analysis, the study by Murillo-Zamora et al [28] 
reported a similar estimate for type-2 diabetes (OR = 1.47, 95% = 1.21-1.56).
Having chronic kidney disease was found to increase mortality risk. Based on six studies, the pooled OR was 
1.57 (95% CI = 1.27-1.93) in the main analysis (Figure 4), and was 1.52 (95% CI = 1.23-1.88) and 1.57 (95% 
CI = 1.27-1.93) in the two sensitivity analyses.
Risk factors that were possibly associated with increased risk for mortality
Cardiovascular disease and coronary heart disease were both found to be possibly associated with increased 
risk for mortality; the findings of main and sensitivity analyses were inconsistent. For cardiovascular diseases, 
the pooled OR in the main analysis was 1.45 (95% CI = 0.98-2.16) based on six studies (Figure 5), where-
as the pooled OR was 1.29 (95% CI = 1.07-1.55) in the sensitivity analysis that excluded low-quality studies. 
For coronary heart disease, the pooled OR in the main analysis was 2.27 (95% CI = 1.23-4.17) based on sev-
en studies (Figure 5), whereas the pooled OR was 1.40 (95% CI = 0.84-2.32) in the sensitivity analysis that 
excluded low-quality studies.
Hypertension was also observed to be possibly associated with an increased risk for mortality as borderline 
lower 95% CI was found in both the main and the sensitivity analysis that excluded low-quality studies, with 
the pooled OR being 1.30 (95% CI = 0.99-1.71) (Figure 5) and 1.09 (95% CI = 0.996-1.19), respectively.
Figure 4. Forest plots showing meta-analysis results for mortality. 
Panel A. Obesity. Panel B. Diabetes. Panel C. Chronic kidney dis-
ease. Obesity is defined as body mass index of >30. N – number of 
subjects, QA – quality assessment score.
Figure 5. Forest plots showing meta-analysis results for mortality. 
Panel A. Cardiovascular diseases. Panel B. Coronary heart diseas-
es. Panel C. Hypertension. N – number of subjects, QA – quality 
assessment score.
Figure 4 Figure 5
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Due to limited (only three) availability of studies, only the main meta-analysis was conducted for chronic lung 
disease, which showed a pooled OR of 1.24 (95% CI = 1.13-1.36), indicating possibly increased risk for mor-
tality (Figure 6).
Several other factors were also found to be possibly associated with increased risk for mortality although no 
meta-analysis could be conducted due to limited studies. These factors include: any comorbidities (as a broad 
category; one study), heart failure (two studies), any immuno-compromised conditions (as a broad category; 
one study), malignancy (two studies), any neurological diseases (two studies) and dementia (two studies). De-
tails about these studies are available in Table S5 in the Online Supplementary Document.
Risk factors that were possibly not associated with increased risk for mortality
Two factors, namely cerebrovascular diseases and hyperlipidaemia, were possibly not associated with increased 
risk for mortality with 95% CI including one, based on four studies and three studies, respectively (Figure 6). 
No sensitivity analyses could be done due to limited studies.
Risk factors that were not associated with increased risk for mortality
Consistent meta-analysis results were observed between the main analysis and sensitivity analyses for chronic 
obstructive pulmonary diseases (COPD), cancer and current smoker, which indicated that these factors were 
not associated with increased risk for mortality (Figure 7).
Risk factors for ICU admission
Being male was associated with an increased risk for ICU admission and the corresponding pooled OR was 
1.82 (95% CI = 1.09-3.03) based on five studies in the main analysis (Figure S1 in the Online Supplementary 
Document), and was 1.35 (95% CI = 1.21-1.51) and 1.34 (95% CI = 1.20-1.50) in the two sensitivity analyses. 
Several factors were possibly associated with increased risk for ICU admission (Table S6 in the Online Sup-
plementary Document): older age (two studies), obesity (one study), use of ACEi (one study) and any immu-
no-compromised condition (one study).
Figure 6. Forest plots showing meta-analysis results for mortality. 
Panel A. Chronic lung diseases. Panel B. Cerebrovascular diseases. 
Panel C. Hyperlipidaemia. N – number of subjects, QA – quality 
assessment score.
Figure 7. Forest plots showing meta-analysis results. Panel A. 
Chronic obstructive pulmonary diseases. Panel B. Current smoker. 
Panel C. Cancer. N – number of subjects; QA – quality assessment 
score.
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Diabetes was possibly not associated with increased risk for ICU admission although only the main analysis 
was conducted among three studies (OR = 2.24, 95% CI = 0.84-5.95). Hypertension was not associated with 
increased risk for ICU admission; the pooled OR was 0.90 (95% CI = 0.78-1.04) based on six studies in the 
main analysis and was 0.91 (95% CI = 0.79-1.06) in the sensitivity analysis that excluded low-quality studies 
(Figure S1 in the Online Supplementary Document).
Risk factors for IMV
Being male and diabetes were associated with increased risk for IMV; the pooled OR was 2.20 (95% CI = 1.50-
3.23) based on six studies and was 1.59 (95% CI = 1.10-2.29) based on four studies, respectively (Figure S2 in 
the Online Supplementary Document). Older age and BMI>35 were possibly associated with increased risk 
for IMV, based on one and three studies, respectively (Table S7 in the Online Supplementary Document).
Hypertension was possibly not associated with increased risk for IMV; the pooled OR was 1.45 (95% CI = 0.42-
4.98) based on three studies (Figure S2 in the Online Supplementary Document).
DISCUSSION
To our knowledge, this is one of the most comprehensive systematic reviews that assessed the full spectrum 
of risk factors for poor outcomes among hospitalised COVID-19 patients. We critically appraised and syn-
thesised all best available evidence from both peer-reviewed publications and non-peer-reviewed preprints. 
We also developed a data interpretation framework that accounted for the strength of evidence and ensured 
consistency and comparability across risk factors and poor outcomes. Based on the framework, we found that 
being male, older age, obesity, diabetes and chronic kidney diseases were associated with risks for poor out-
comes with the greatest strength of evidence. The full list of reported risk factors with different levels of evi-
dence strength is available in Table 2.
Although several factors, such as COPD, cancer, current smoker and hypertension, were interpreted as not being 
associated with increased risk for poor outcomes, it should be noted that this is based on currently available evi-
Table 2. Summary of data synthesis interpretations of risk factors for poor outcomes among hospitalised COVID-19 patients




Mortality • Male (20 studies; OR = 1.32, 95% 
CI = 1.18-1.48)
• Any comorbidities (1 study) • Cerebrovascular 
disease (4 studies)
• COPD  
(5 studies)
• Older age (10 studies; OR = 1.05 95% 
CI = 1.04-1.07, per one year of age increase)
• Any cardiovascular diseases (6 studies) • Hyperlipidaemia 
(3 studies)
• Cancer  
(4 studies)
• Obesity (4 studies; OR = 1.59, 95% 
CI = 1.02-2.48)
• Coronary heart disease (7 studies) • Current smoker 
(5 studies)
• Diabetes (11 studies; OR = 1.25, 95% 
CI = 1.11-1.40)
• Hypertension (9 studies)
• Chronic kidney disease (6 studies; 
OR = 1.57,95% CI = 1.27-1.93)
• Heart failure (2 studies)
• Chronic lung disease (3 studies)
• Any immuno-compromised condition  
(1 study)
• Malignancy (2 studies)
• Any neurological diseases (2 studies)
• Dementia (2 studies)
ICU admission • Male (5 studies; OR = 1.82, 95% CI = 1.09-
3.03)
• Older age (2 studies) • Diabetes  
(3 studies)
• Hypertension  
(6 studies)• Obesity (1 study)
• Use of ACEi (1 study)




• Male (6 studies; OR = 2.20, 95% CI = 1.50-
3.23)
• Older age (1 study) • Hypertension  
(3 studies)
• Diabetes (4 studies; OR = 1.59, 95% 
CI = 1.10-2.29)
• BMI>35 (2 studies)
OR – odds ratio, BMI – body mass index, COPD – chronic obstructive pulmonary disease, ACEi – angiotensin-converting-enzyme inhibitor
*Interpret with caution: risk factors that apparently show no association with outcome could be due to lack of statistical power.
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dence that might lack the necessary statistical power. As a result, we caution against any interpretations that these 
characteristics are not risk factors. For those findings that were interpreted as being (definitively) or possibly being 
associated with increased risk for poor outcomes, we caution against interpreting these effects as causal effects.
We reported that there was an increased risk of 5% (95% CI = 4-7) for mortality given one year of age increase, 
which was based on studies that included age as a continuous variable in their models. Although this indicated 
that older age was an important risk factor, the finding did not necessarily imply that there was a linear rela-
tionship between age and risk for mortality. With this caveat, we caution against any quantitative interpreta-
tions of our findings (eg, 5% of increase in the example above) regarding age.
Our study has several strengths. First, we limited our selection criteria to COVID-19 patients that were lab-
oratory-confirmed to reduce misclassification bias at study level. Second, we limited our selection criteria to 
studies that reported the adjusted effect (eg, through multivariate analysis) to reduce confounding at study 
level. Third, we selected not to include composite poor outcomes that often varied by study to ensure com-
parability. Fourth, to address potential publication bias, we included evidence from both peer-reviewed and 
non-peer-reviewed sources and appraised the quality of all evidence. Finally, we developed a data interpreta-
tion framework that was informed by both quantity and quality of the evidence.
Our study does have limitations. First, we focused on hospitalised COVID-19 patients. This could lead to bi-
ased estimates of risk for some risk factors, in particular when access to health care differed between those 
with that risk factor and those without. For example, patients with certain comorbidities might be more like-
ly to be hospitalised with COVID-19 symptoms than those without. This means that the clinical severity of 
COVID-19 among hospitalised patients with certain comorbidities could be overall lower than those without 
certain comorbidities, resulting in selection bias towards null hypothesis (if these comorbidities truly increase 
risk for poor outcomes). Second, as an evidence review from a global perspective, we were unable to account 
for local contexts in our analysis, such as social distancing and lockdowns, access to health care (especially at 
the beginning of the pandemic) and access to personal protective equipment. These local contexts could vary 
greatly across regions and might contribute to the heterogeneity of the findings. Third, we were unable to as-
sess effect-modifiers due to lack of relevant data. For example, age and/or sex could be effect modifier(s) for 
some comorbidities [45]. Fourth, we did not include non-English papers in our review. Fifth, our searches 
yielded prior systematic reviews but we did not have the resource to scrutinise the included studies for inclu-
sion in this review; we have summarised those prior reviews in the appendix (Table S1 in the Online Sup-
plementary Document). Finally, we only included data published between January and May 2020, and it is 
likely that inclusion of data from studies published later could alter some of our findings and interpretation.
CONCLUSIONS
In conclusion, our review provides not only an appraisal and synthesis of evidence on the risk factors of COVID-19 
poor outcomes, but also a data interpretation framework that could be adopted by relevant future research.
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